Combination Therapy of AK112 With Chemotherapy and/or Olaparib in Platinum-sensitive Ovarian Cancer

This study tests a combination of an immunotherapy drug (AK112, which targets both PD-1 and VEGF), chemotherapy, and/or a PARP inhibitor (olaparib) in women with platinum-sensitive ovarian cancer — meaning cancer that responded to platinum-based chemotherapy but has since come back more than 6 months after the last treatment. **You may be eligible if...** - You are a woman aged 18 or older - You have been diagnosed with epithelial ovarian, fallopian tube, or primary peritoneal cancer - Your cancer is platinum-sensitive (came back more than 6 months after last platinum-based treatment) - You have measurable disease on a scan - You are physically functional (ECOG 0–1) **You may NOT be eligible if...** - Your cancer is of a mucinous type or other rare subtype - You have brain metastases - You have an active autoimmune disease - You have had previous immunotherapy treatment - You are pregnant or breastfeeding - You have active hepatitis B or C, or HIV - You have a history of interstitial lung disease Talk to your doctor to see if this trial is right for you.